13F Holdings
中文EN

GOVX GeoVax Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 832489 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-84.8%
TTM net income YoY12.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,523.4%
Net margin-2,507.3%
FCF margin-2,236.0%
EBITDA margin-2,515.9%

Returns

ROE-509.3%
ROA-309.3%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets83.4%
Debt / equity0.00x
Current ratio1.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-33.6%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.49M$3.95M$0$81,526$385,501
R&D expense$18.12M$23.71M$20.72M$9.12M$15.55M
SG&A expense$6.01M$5.39M$6.02M$4.99M$3.58M
Operating income-$21.64M-$25.14M-$26.74M-$14.03M-$18.75M
Interest expense$0$21,375$0$0$1,286
Income tax————$0
Net income-$21.46M-$24.99M-$25.97M-$14.02M-$18.57M
EBITDA-$21.57M-$25.05M-$26.67M-$13.97M-$18.71M
EPS (basic)-22.40-120.46-14.29-12.39-3.04
EPS (diluted)————-3.04
Weighted avg. shares (diluted)————6.10M
Balance sheet
Cash & equivalents$3.09M$5.51M$6.45M$27.61M$11.42M
Receivables$0$659,409$0——
Current assets$5.31M$7.93M$7.89M$28.94M$11.63M
PP&E, net$108,830$149,974$209,689$234,912$156,938
Total assets$6.34M$8.16M$9.28M$31.35M$11.80M
Current liabilities$1.94M$3.11M$3.52M$4.75M$5.44M
Total liabilities$2.52M$3.11M$3.52M$4.75M$7.44M
Shareholders' equity$3.83M$5.05M$5.76M$26.60M$4.36M
Shares outstanding72,173421,4751.98M1.76M6.38M
Cash flow statement
Operating cash flow-$21.47M-$24.68M-$25.17M-$19.03M-$11.20M
Capital expenditure$27,612$20,653$48,946$134,258$47,718
Free cash flow-$21.50M-$24.70M-$25.22M-$19.16M-$11.24M
Investing cash flow-$27,612-$20,653-$48,946-$134,258-$47,718
Financing cash flow$19.08M$23.75M$4.06M$35.35M$12.78M
Depreciation & amortization$68,756$95,368$74,169$56,284$38,521
Stock-based compensation$1.12M$528,644$1.07M$902,074$369,987

Free plan shows the latest 5 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.